A study looking at using everolimus for advanced kidney cancer
Cancer type:
Status:
Phase:
This study looked at using everolimus for kidney cancer that has spread to another part of the body.
It was for people who were having surgery to remove the kidney as part of their treatment.
Cancer Research UK supported this trial.
More about this trial
When this trial was done, doctors could treat advanced kidney cancer with surgery or a 
Everolimus is a type of targeted drug. At the time of the trial, doctors used everolimus advanced kidney cancer that has come back. It works by stopping a protein called mTOR from working properly and so may stop the cancer from growing or slow it down.
The researchers in this trial thought that everolimus before surgery may help people with advanced kidney cancer.
The main aims of this study were to find out:
- how safe it is to give everolimus to people before and after having surgery to remove the kidney
- what the side effects are
- how well everolimus works after surgery for people with advanced kidney cancer
Summary of results
This trial closed earlier than planned. This was because there were better available treatments for kidney cancer that had come back.
Only 7 people joined the trial before it closed. So there wasn't enough information to analyse and the trial didn't produce any results.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Dr James Larkin
Supported by
Cancer Research UK
NIHR Clinical Research Network: Cancer
Novartis
The Royal Marsden NHS Foundation Trust
Other information
This is Cancer Research UK trial number CRUKE/10/047.
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
